Carb-X Website, Blog & Press Pages

Carb-X Website, Blog & Press Pages - aVenture

Carb-X - Library

carb-x.orgCrawled Oct 15, 2026

2 pages

Phages: A promising alternative in the age of antibiotic resistance?/carb-x-news/phages-a-promising-alternative-in-the-age-of-antibiotic-resistance
Science vs. superbugs: A new wave of solutions is on the way/carb-x-news/science-vs-superbugs-a-new-wave-of-solutions-is-on-the-way

9 pages

Antibiotic Resistance/news/antibiotic-resistance
INNOVATION NEWS NETWORK | Henry Skinner, PhD, CEO of the AMR Action Fund, discusses how AMR is affecting cancer care across Europe and outlines what can be done about it.
Antimicrobial resistance triggers race to develop phage alternatives/carb-x-news/antimicrobial-resistance-triggers-race-to-develop-phage-alternatives
The article discusses phages, viruses that destroy bacteria, as potential supplements to waning antibiotics and describes regulatory and funding challenges raised by researchers and entrepreneurs.
CARB-X awards Seres Therapeutics $2.5M and possibly $3.1M more if certain milestones are met to develop a microbiome therapeutic to prevent serious bacterial infections and graft versus host disease i/carb-x-news/carb-x-awards-seres-therapeutics-2-5m-and-possibly-3-1m-more-if-certain-milestones-are-met-to-develop-a-microbiome-therapeutic-to-prevent-serious-bacterial-infections-and-graft-versus-host-disease-i
CARB-X is backing Seres Therapeutics Inc. of Cambridge, MA, to develop a preclinical microbiome therapeutic to prevent serious bacterial infections.
CARB-X News/news/carb-x-news
CARB-X today announced that Richard Alm, Ph.D., has been appointed Chief of Research and Development (R&D) following a competitive global recruitment process.

6 pages

Dr. Barry Eisenstein/team/dr-barry-eisenstein
Barry Eisenstein received his MD from Columbia University and trained in internal medicine and infectious diseases at the University of North Carolina. He has spent his career in academia.
Ed Buurman, PhD, MBA/team/ed-buurman
Ed spent more than 20 years in large pharma (Pfizer, AstraZeneca) and biotech (Scriptgen/Anadys Pharmaceuticals), focusing on therapeutic and preventive approaches to infections caused by viruses, bacteria, and fungi.
James Southard, JD/team/james-southard-jd
James brings more than 12 years of legal experience to his role with CARB-X. He graduated from Northeastern University in 2004 and The New England School of Law in 2009.
Kathleen Chardavoyne, MBA/team/kathleen-chardavoyne
Kathleen is a certified project manager with an MBA and more than a decade of experience designing, implementing and reporting on systems and processes at complex, global organizations.

6 pages

About/about
Advisory Board/about/advisory-board
CARB-X has pre-award advisory boards that review proposals and post-award boards that review project progress. Members complete conflict-of-interest reviews and are excluded from decisions on applications where they have a conflict.
Global Threat/about/global-threat
No approved classes of antibiotics have been discovered since 1962 for the most dangerous types of bacteria – Gram-negatives – and innovations to improve the diagnosis and prevention of drug-resistant infections have been slow.
Joint Oversight Board/about/joint-oversight-board
CARB-X is governed by the Joint Oversight Board, which includes representatives of funding organizations and an independent chair. The board sets the overall portfolio.

1 page

Contact/contact
Boston University School of Law 771e Commonwealth Avenue Boston, MA 02215, United States carbxpr@bu.edu linkedin.com/company/carb-x/ twitter.com/CARB_X

1 page

Homepage/
CARB-X plays a vital role in the drug development pipeline, bridging basic research and clinical development partners.